Advances in the treatment of hyperglycaemia include glucagon-like peptide-1 (GLP-1) receptor agonists, such as exenatide and liraglutide, and dipeptidyl peptidase-4 (DPP-4) inhibitors, such as sitagliptin and saxagliptin. This evidence concerns the gene GCG and Hyperglycemia.